RTGN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: January 15, 2025
Report Source: 2024 3rd Quarter Report
RetinalGenix Technologies Inc. Stock Analysis RTGN
United States Health Care Micro Cap Report: RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Read More RetinalGenix Technologies Inc (RTGN) Chart
Key Statistics of RetinalGenix Technologies Inc (RTGN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$4.00Volume
500.00P/E Ratio (TTM)
-52 Week Range
Market Cap
75.02MAvg. Volume
500.00Dividend Yield
-Financial Metrics & Statements of RetinalGenix Technologies Inc (RTGN)
FAQ's for RetinalGenix Technologies Inc (RTGN)
- According to Musaffa’s Shariah screening methodology, RetinalGenix Technologies Inc (RTGN) is currently classified as NOT HALAL as of January 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.